This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts initiated coverage on five stocks with bullish outlooks. BMO Capital's Connor Mackay rated Insmed (INSM) Outperform with a $192 price target, while Malcolm Hoffman rated Axsome Therapeutics (AXSM) Outperform with a $310 target. Compass Point's Rob Simone gave American Healthcare REIT (AHR) a Buy rating at $70. BMO's Connor Murphy rated Trevi Therapeutics (TRVI) Outperform at $36, and Rodman & Renshaw's Seema Sheoran rated Eledon Pharmaceuticals (ELDN) Buy at $12.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

BMO Capital analyst Connor Mackay initiated coverage on Insmed Inc (NASDAQ:INSM) with an Outperform rating and announced a price target of $192. Insmed shares closed at $107.02 on Monday. See how other analysts view this stock.
BMO Capital analyst Malcolm Hoffman initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM) with an Outperform rating and announced a price target of $310. Axsome Therapeutics shares closed at $221.64 on Monday. See how other analysts view this stock.
Compass Point analyst Rob Simone initiated coverage on American Healthcare REIT Inc (NYSE:AHR) with a Buy rating and announced a price target of $70. American Healthcare shares closed at $56.66 on Monday. See how other analysts view this stock.
BMO Capital analyst Connor Murphy initiated coverage on Trevi Therapeutics Inc (NASDAQ:TRVI) with an Outperform rating and announced a price target of $36. Trevi Therapeutics shares closed at $16.77 on Tuesday. See how other analysts view this stock.
Rodman & Renshaw analyst Seema Sheoran initiated coverage on Eledon Pharmaceuticals Inc (NASDAQ:ELDN) with a Buy rating and announced a price target of $12. Eledon Pharmaceuticals shares closed at $3.86 on Monday. See how other analysts view this stock.

Considering buying INSM stock? Here’s what analysts think:

Photo via Shutterstock

BMO Capital analyst Connor Mackay initiated coverage on Insmed Inc (NASDAQ:INSM) with an Outperform rating and announced a price target of $192. Insmed shares closed at $107.02 on Monday. See how other analysts view this stock.
BMO Capital analyst Malcolm Hoffman initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM) with an Outperform rating and announced a price target of $310. Axsome Therapeutics shares closed at $221.64 on Monday. See how other analysts view this stock.
Compass Point analyst Rob Simone initiated coverage on American Healthcare REIT Inc (NYSE:AHR) with a Buy rating and announced a price target of $70. American Healthcare shares closed at $56.66 on Monday. See how other analysts view this stock.
BMO Capital analyst Connor Murphy initiated coverage on Trevi Therapeutics Inc (NASDAQ:TRVI) with an Outperform rating and announced a price target of $36. Trevi Therapeutics shares closed at $16.77 on Tuesday. See how other analysts view this stock.
Rodman & Renshaw analyst Seema Sheoran initiated coverage on Eledon Pharmaceuticals Inc (NASDAQ:ELDN) with a Buy rating and announced a price target of $12. Eledon Pharmaceuticals shares closed at $3.86 on Monday. See how other analysts view this stock.

Considering buying INSM stock? Here’s what analysts think:

Photo via Shutterstock